Integer Holdings beats Q3 sales, profit estimates

Integer Holdings

23/10/2025 13:14

Overview

Integer Q3 2025 sales rose 8% to $468 mln, beating analysts' expectations

Adjusted EPS for Q3 2025 increased 25% to $1.79, beating consensus

Outlook

Integer expects 2025 sales between $1.840 bln and $1.854 bln

Company anticipates 2025 adjusted EPS of $6.29 to $6.43

Integer forecasts 2026 organic sales flat to up 4%

Result Drivers

CARDIO & VASCULAR GROWTH - Sales increased 15% driven by new product ramps and acquisitions in electrophysiology and neurovascular

NEUROMODULATION GROWTH - Growth driven by emerging neuromodulation customers with PMA products, offset by planned decline in spinal cord stimulation

OTHER MARKETS DECLINE - Sales decreased 16% due to planned multi-year exit from portable medical market

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$468 mln
$466.45 mln (9 Analysts)
Q3 Adjusted EPS
Beat
$1.79
$1.67 (8 Analysts)
Q3 Adjusted Net Income
Beat
$63 mln
$59.80 mln (7 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Integer Holdings Corp is $137.50, about 21.5% above its October 21 closing price of $107.94

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release: ID:nGNX5l6qGY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)